Key result
Intravenous glucagon increased serum IGFBP-1 concentrations at 90 minutes in healthy subjects, GH-deficient patients, and IDDM patients.
Why the study?
Does intravenous glucagon stimulate insulin-like growth factor binding protein-1 (IGFBP-1) secretion in healthy subjects and patients with pituitary insufficiency or insulin-dependent diabetes mellitus?
Does intravenous glucagon stimulate insulin-like growth factor binding protein-1 (IGFBP-1) secretion in healthy subjects and patients with pituitary insufficiency or insulin-dependent diabetes mellitus?
Glucagon stimulates IGFBP-1 secretion despite increases in glucose and insulin, suggesting it acts as a direct stimulator of IGFBP-1.
Answers are grounded in this paper and cite their sources.
Glucagon may directly stimulate IGFBP-1 independent of glucose/insulin; hypothesis-generating in small cohorts and should not yet change practice.
Glucagon (1-1.5 mg) was administrated iv as a bolus dose to healthy individuals (n = 7), patients with GH deficiency (n = 14), and patients with insulin-dependent diabetes mellitus (IDDM; n = 6). Thereafter, blood samples for determination of serum glucose, insulin, insulin-like growth factor-binding protein-1 (IGFBP-1), GH, and insulin-like growth factor-I (IGF-I) concentrations were collected for 180 min. IGFBP-1 concentrations increased significantly in response to glucagon, with maximal values observed at 90 min [in healthy subjects from 36 +/- 6 to 58 +/- 10 micrograms/L (P < 0.05), in GH-deficient patients from 36 +/- 4 to 54 +/- 6 micrograms/L (P < 0.001), and in IDDM patients from 115 +/- 18 to 167 +/- 27 micrograms/L (P < 0.05)]. The IGFBP-1 elevation was delayed in relation to the glucagon-induced increase in glucose and insulin concentrations. When the groups were combined, the individual IGFBP-1 peak value observed at 90 min was inversely correlated to the individual peak value of insulin observed at 15-30 min (r = -0.743; P < 0.001). In GH-deficient patients, serum GH concentrations remained undetectable (< 0.2 micrograms/L), and IGF-I concentrations were unchanged after the glucagon injection. In healthy subjects and IDDM patients, mean GH levels did not change significantly, whereas mean IGF-I concentrations decreased slightly at 30 min. In conclusion, glucagon increased serum IGFBP-1 concentrations in spite of increases in glucose and insulin. These results suggest that glucagon is a stimulator of IGFBP-1.
No takes yet. Share an insight, caveat, or question.
Hilding et al. (1993) studied Healthy, Growth Hormone deficiency, Insulin-dependent diabetes mellitus (n=27). Glucagon vs. Baseline was evaluated on Serum IGFBP-1 concentrations at 90 minutes (p=<0.05). Intravenous glucagon increased serum IGFBP-1 concentrations at 90 minutes in healthy subjects, GH-deficient patients, and IDDM patients.
Synapse has enriched 10 related papers. Consider them for comparative context: